




**THE UROLOGY FOUNDATION  
TRUSTEES' REPORT & FINANCIAL STATEMENTS  
FOR THE YEAR ENDED DECEMBER 2023**

**“THE WAY AHEAD 2023-2025”**



## Contents

Statement from the Chair .....	3
Overview of the year .....	3
Statement from the Chief Executive, Rebecca Porta .....	4
Statement from the Chief Executive, Rebecca Porta ( <i>continued</i> ) .....	5
<b>Objectives and Activities .....</b>	<b>6</b>
Our Vision and Mission .....	6
Our Aims .....	6
Our Values .....	6
What we do .....	6
Public Benefit .....	7
Grants policy .....	7
<b>Achievements and Performance in 2023 .....</b>	<b>8</b>
1. Our Strategy: The Way Ahead 2023-2025 .....	8
2. Our Research Programme .....	8
3. Improving knowledge and skills through education and training .....	12
<b>Financial Review .....</b>	<b>19</b>
Financial Results of Activities & Events .....	19
Fundraising .....	19
Reserves & Liquidity Policy .....	20
Statement of going concern .....	21
Investments Policy .....	21
Remuneration policy .....	21
Pensions policy .....	21
Equal opportunities and diversity policy .....	21
Principal risks and uncertainties .....	21
<b>Structure, Governance &amp; Management .....</b>	<b>23</b>
Charity Governance Code .....	23
Trustee Recruitment, Training and Induction .....	23
Appointment & Election .....	23
Relationships with Related Parties .....	24
Representation on Other Bodies .....	24
<b>Reference and administrative details .....</b>	<b>25</b>
Trustees .....	25
Registered Office .....	25
Auditors .....	25
<b>Trustees' &amp; Directors' Responsibilities in the Preparation of Financial Statements .....</b>	<b>26</b>
Auditor .....	26
Statement as to disclosure of information to the auditor .....	26



## Statement from the Chair

### Overview of the year

Welcome to our Annual Report for 2023.

1 in 2 people will suffer from a urological disease or condition in their lifetime. This includes urological cancers - prostate, kidney, bladder and male reproductive cancers - and non-malignant conditions including incontinence, urinary tract infections and kidney stones.

People diagnosed and living with these urological cancers and conditions seek information, support and interventions to help navigate the health and social care system and the challenges of everyday life. We are the only charity in the UK representing the entire spectrum of urology health and disease and through our investment in world class research, training and education programmes, raising awareness and driving policy change, we are in the unique position of being the “voice” of the urology community.

This year we launched our new strategy “The Way Ahead 2023-2025”. The strategy is a bold, exciting and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a “voice” in shaping future research agendas and priority areas.

“The Way Ahead 2023-2025” strategy sets out eight priorities:

- Priority 1:** Significantly accelerate the progress and breakthroughs in urological research.
- Priority 2:** Invest in our scientific and medical communities, support early career researchers and fund new, innovative ideas.
- Priority 3:** Facilitate collaborations and partnerships with individual research leaders and research institutes, charities, industry and partners who share our common goals.
- Priority 4:** Drive change in behaviours, beliefs, policy and practice as a result of research outcomes.
- Priority 5:** Campaign for further investment in research through working with patients, their families, health and social care professionals, researchers, policy makers, charities, government, industry, funding bodies and those with an interest in research.
- Priority 6:** Place people affected by urological disease at the heart of research, ensuring they are involved at all stages of research design, delivery, analysis and dissemination.
- Priority 7:** Give a voice to the people affected by or at risk of urological disease ensuring they have the opportunity to be heard, to influence and drive change.
- Priority 8:** Transforming The Urology Foundation- ensuring we can build on our success and deliver our objectives, for the benefit of our stakeholders.

We are ambitious for the future and what can be achieved. Ensuring patients and their families have better outcomes, live longer, and with a better quality of life, remains at the heart of our work.



Mary Garthwaite, Chair



## Statement from the Chief Executive, Rebecca Porta

This has been another successful year for the Foundation thanks to the support and commitment of our stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters.

We awarded eight new Research and Innovation Projects and five Small Project Grants covering kidney and prostate cancers, urinary tract infections, urothelial cancer and the management of Haematuria. We introduced new training and career development opportunities, study and travel grants to support our scientific and medical communities and encourage the “rising stars” in urology. The TUF Trials Unit (TTU), a partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen delivered impressive results, supporting urologists from across the UK to put forward their ideas and applications for research. TTU has already helped secure an impressive £6.1 million in funding for the research community from our initial investment of £180,000 (£60,000 per annum).

1 in 2 of us will be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life. Throughout the year we provided media spokespeople, ran campaigns and awareness events, presented at conferences, met with decision makers and influencers and worked with a wide range of stakeholders to drive policy change. A key focus this year has been prostate cancer and bladder health - with opportunities to attend Roundtables and contribute to discussions and recommendations on the care pathway and improving outcomes.

Awareness highlights include the annual Urology Awareness Month, World Continence Week, a “Catheter Care Challenge” at the House of Commons, a Parliamentary Reception and a series of community-based events encouraging anyone concerned by “blood in pee” to contact their GP practice. This was part of the NHS England “Help Us, Help You” symptom awareness campaign. In November we were delighted to welcome our first Director of Communications and Policy, Laura Thorne to help drive forward our awareness, campaigning and policy programme.

As part of our commitment to put our patient community at the centre of everything we do, we launched our Patient and Public Involvement Programme to bring together researchers, patients, carers and those with an interest in urology. The Programme offers an opportunity to influence and shape research including planning, design, management, evaluation and communication and identifying priorities.

Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the generosity of our wonderful supporters. Income rose by over 9.6% from £1,355,713 in 2022 to £1,470,272 in 2023. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. Sincere thanks to all those who have supported us.





## Statement from the Chief Executive, Rebecca Porta *(continued)*

It is two years since I joined The Urology Foundation as Chief Executive and as each month passes my ambition for what I want the Foundation to achieve continues to grow. “The Way Ahead 2023-2025” sets out our ambitions and goals for the future and already we are making great progress towards the eight priorities outlined in the strategy. The aim is to improve the outlook for people affected by urological cancers and conditions ensuring they have better outcomes and a better quality of life. I hope that you will join me in this important and exciting journey.

A handwritten signature in grey ink that reads "R. Porta". The signature is written in a cursive style with a horizontal line underneath the name.

**Rebecca Porta, Chief Executive**



## Objectives and Activities

The Urology Foundation's objects are to:

“Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work.”

### Our Vision and Mission

We see a world where people will not die early from urological cancers and diseases, and where people with bladder, kidney and prostate problems can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research and training, so patients receive the best possible treatment and care and fewer lives are devastated.

### Our Aims

The Urology Foundation is committed to reducing the suffering caused by urological diseases. We work with researchers, urology and health care professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

### Our Values

In undertaking our remit we are:

- **Ambitious** to see UK urology care, treatment and practice is the best in the world.
- **Dedicated** to beating all urology diseases through research and training.
- **Proud** of working in urology and committed to transforming the lives of people with a urology condition.
- **Collaborative**; working with researchers, urologists, nurses and health care professionals, influencers and decision makers, charity partners, patients and their families we are improving the nation's urology care.

### What we do

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.



Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

## Public Benefit

The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this trustees' annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the trustees from time to time shall decide.

In addition, the charity provides information on urological cancers and conditions, raises awareness, campaigns and drives policy change.

## Grants policy

The Foundation advertises its programmes and awards on its website, through its professional e-newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial Partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Clinical Research Network (CRN) support subject to meeting the standard study eligibility criteria.



# Achievements and Performance in 2023

## 1. Our Strategy: The Way Ahead 2023-2025

In April our new strategy “The Way Ahead 2023-2025” was launched. The strategy is a bold, exciting and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research and ensuring they have a “voice” in shaping future research agendas and priority areas.

“The Way Ahead 2023-2025” strategy sets out eight priorities:

**Priority 1.** Significantly accelerate the progress of urological research

**Priority 2.** Invest in our scientific and medical communities

**Priority 3.** Facilitate collaborations and partnerships

**Priority 4.** Drive change as a result of research outcomes

**Priority 5.** Campaign for further investment in research

**Priority 6.** Place people affected by urological disease at the heart of research

**Priority 7.** Give a voice to the people affected by or at risk of urological disease

**Priority 8.** Transforming The Urology Foundation.

## 2. Our Research Programme

### *Innovation & Research Awards*

Our Innovation & Research Award funds projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that eight awards totalling £431,592 were made in 2023 (in 2022 there were 8 awards totalling £375,096). The eight projects were:

Impact of body composition on patients with advanced prostate cancer: The main treatment for advanced prostate cancer is androgen deprivation therapy (ADT), which lowers the male hormone called testosterone. ADT stops prostate cancer growth, but can cause men to lose muscle and to gain fat. This can make men weaker reducing mobility and quality of life. The STAMPEDE trial has studied more than 12,000 men with advanced prostate cancer, testing different combinations of treatments. This project will use images from these men to look at how muscle and fat change with different combinations of ADT. It will determine if muscle and fat distributions are linked to how well the treatment works and if patients experience greater side-effects. This work will be the world’s largest study of body changes in men with advanced prostate cancer. The results will allow us to understand how different treatments act to drive these changes, enabling tailoring treatment to the individual.

Using a living model of the human bladder to study Urinary Tract Infections (UTIs): This project will use a living model of the human bladder to study how antimicrobial resistance (AMR) develops during the treatment of urinary tract infection (UTIs) and to study the effects AMR mutations have on Escherichia coli, the most common bug in UTIs. It will use antibiotics recommended for the treatment of UTIs, with E. coli isolated from the urine of patients with UTIs. The data produced in this study will be used as an evidence base to guide the sustainable use of antibiotics for the treatment of UTIs. Additionally, the researchers will generate a database of possible mutations which can arise during antibiotic therapy for UTIs and the corresponding effect on the activity of an antibiotic(s). This will



improve understanding of how the use of antibiotics in humans directly affects the development of AMR, leading to improved patient outcomes and reduced healthcare and economic burdens.

Investigating Immune Priming Interventions in Kidney Cancer: Worldwide, over 40,000 people are diagnosed with a kidney tumour every year. An operation to remove the tumour is currently the only way to completely cure the cancer. This operation is associated with the risks of having major surgery. There are several new treatments which don't involve surgery called ablation treatments (including freezing and radiotherapy) which can destroy kidney tumours. The first aim of this project is to find out if any of these ablation treatments can increase the activity of our immune system. A more active immune system has been shown to lead to better results for patients. The second aim will see if changes in the immune system, detectable in a blood test can be used to monitor patients, to tell if the tumour will grow quickly or slowly. Both these aims could reduce the number of patients undergoing major surgery and the risks associated with it.

DESENT biomarker for the prediction of prostate cancer outcomes: This study is developing a test to identify more aggressive cancer that can be used by hospitals, based on patterns of genes being turned on or off in cancer cells at an early stage of the disease. In this project, prostate cancer tissue, from patients who have had their whole prostate surgically removed to treat their cancer, is compared to the results obtained from their urine and biopsy samples. The researchers will measure whether genes are switched off or on for all genes in urine, biopsy material and whole prostate samples. They have also collected tissue and genetic information from a separate group of patients with multiple, separate tumours within their prostate and are aiming to look at genetic similarities and differences between these tumours. Through analysis of the cell markers, they hope to determine classifications that pick up on aggressive cancers. This study will provide a greater understanding of how a test of cancer aggressiveness actually works, bringing it closer to being used as a test in clinical use to help patients make decisions about their treatment.

How Oestrogen, or lack of, affects the susceptibility of post-menopausal women to recurrent urinary tract infections: Urinary tract infections (UTIs) are common in post-menopausal women. Treatment is usually antibiotics, but re-infections are problematic often resulting in multi-drug resistant bacteria. It is known that women prescribed vaginal oestrogen creams by their doctor have reduced susceptibility to re-infections, but it is not really understood why. The research proposition is that oestrogen treatment alters the physical structure of genetic material or DNA, which helps protect the urinary tract from infection. The project will use samples from postmenopausal women who have either been prescribed vaginal oestrogen or not, and compare the DNA structures of key genes functioning to protect the urinary tissues from bacterial infections. Results will provide better knowledge of how oestrogen helps reduce UTIs and support the development of non-antibiotic UTI therapies, including oestrogen mimics, to reduce antibiotic use.

A Postal Pilot Study for a National Lynch Syndrome Urothelial Cancer Screening Programme: Newcastle University has designed a urine-based cancer test (the Newcastle MSI-Plus assay). This test identifies characteristic changes in urine samples when there is a cancer in the urinary tract that has been caused by Lynch syndrome, an inherited condition associated with an increased risk of urinary tract cancer. The project aims to establish if this test could become a screening test for urinary tract cancers for individuals with Lynch Syndrome. Researchers will collect urine samples from a minimum of 100 healthy individuals with Lynch Syndrome. They expect that most of these tests will be 'negative' or 'normal' and this sample collection will provide proof that healthy individuals with Lynch Syndrome get an accurate result. They will also collect urine samples from patients known to have a urinary tract cancer to gather data about the ability of the urine test to pick up these cancers within urine.

Ex vivo real-time analysis of radical prostatectomy margins using fluorescence confocal microscopy (FCM): One of the most common curative treatment options for localised prostate cancer is radical prostatectomy (RP); a keyhole operation to remove the whole prostate. In some cases, cancer extends very close to the surface of the prostate (the 'margin') and there is a risk of some cancer





being left behind after RP. Leaving cancer behind may mean it could spread, potentially leading to earlier death. There is currently no accepted technique to test the margins for cancer during RP. This study will test a new technology called fluorescence confocal microscopy (FCM) on the prostate immediately after it is removed during RP. We hope to show that FCM is as accurate as a pathologist in detecting cancer at the surgical margins and, in the future, be used to guide surgeons to remove areas of cancer that have been missed. We are grateful to the John Black Charitable Foundation for their funding for this award.

Augmenting the efficacy of sonodynamic therapy against metastatic castration-resistant prostate cancer This project will form the basis towards the design and development of new combination treatments with significantly improved therapeutic outcomes for prostate cancer. The team has developed a treatment called sonodynamic therapy utilizing sound waves and small particles that can eradicate tumours within the prostate in a targeted and minimally invasive manner, with minimum side effects. A large proportion of patients develop prostate cancer types that are very aggressive and difficult to treat with existing therapies. These types of cancer also exhibit relatively increased resistance to sonodynamic therapy, and a potential resistance mechanism that lowers the efficacy of this therapeutic approach has been identified. This research will investigate what prostate cancer types are equipped with the newly discovered mechanism of resistance. Then, it will investigate the efficiency of a non-toxic agent to reduce any relative resistance phenomena to sonodynamic therapy, as well as to radiotherapy and certain chemotherapies. We are grateful to the John Black Charitable Foundation for their funding for this award.

### ***Smaller Research Projects Fund***

The Smaller Research Projects fund is focused on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within 2 years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care.

We are pleased to report that five awards totalling £50,000 were made in 2023 (in 2022 there were four awards totalling £40,000). The projects were:

- A UK multi-centre validation of the novel TARGET scoring system for detecting in-field recurrences after focal therapy for prostate cancer.
- Improving ways of detecting susceptibility to myocardial (heart) injury after kidney cancer surgery.
- Reducing the Morbidity of Radical Prostatectomy - helping men to regain their erections after surgery for prostate cancer.
- What a “good improvement” looks like post BPH Surgery: The patients’ Perspective.
- Investigating the barriers to inclusivity in prostate cancer and exercise research within the NHS.

A £10,000 award was also made to BURST (British Urology Researchers in Surgical Training), who are a UK-based research collaborative that designs and delivers large-scale research studies in urology, for their study: Ward Admission of Symptomatic Haematuria: An Observational multicentre study (WASHOUT).

### ***Strategic research funding***

In 2023 the Foundation awarded a grant of £167,000 to Professor Kelly of UCL, for his research “Developing algorithms from biometric data to predict complications occurring in patients during and after chemotherapy (HALO Trak).” The HALO Trak study follows on from research emanating from the iROC Trial, which established that robot-assisted bladder cancer surgery reduced time spent in hospital, reduced readmissions, and led to better levels of fitness and a quality of life. It also showed that there was a striking reduction in blood clots in patients receiving robotic surgery; indicating a safe surgery with patients benefiting from far less complications, early mobilisation and a quicker return to normal life.



The HALO-Trak study is examining ongoing recovery after surgery using smart, wearable tracking devices to monitor patients remotely, to assess whether a decline in fitness signifying a potential relapse or recurrence of cancer can be detected through biometric readings. We are grateful to the Champniss Foundation and the Champniss Charitable Foundation for their joint funding of this research.

### ***The TUF Trials Unit***

In 2020 the TUF Trials Unit (TTU) launched in partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen. The unit is led by Professor Graeme MacLennan, a medical statistician and Professor James N'Dow, a consultant urologist. The role of the TTU is to identify promising and important research ideas from urology units and provide a team of medical investigators to bring those ideas to fruition. This approach enables more high-quality urology trials to take place, leading to better care, quicker recovery times and fewer long-term issues. Successful trials are catalysts for change, provide potential for transformational discoveries and drive improvements in treatment and care.

With an initial investment of £180,000 (£60,000 per annum) we are pleased to report the TTU has leveraged this funding to secure an impressive £6.1 million in funding from the National Institute of Health and Social Care (NIHR) to conduct three large-scale, multi-centre trials across the United Kingdom (PARTIAL, ELIPSE, The FOLLOW UP Study). Each of these studies addresses major gaps in the evidence base for prostate and kidney cancer and findings will feed directly into national and international guidelines when completed.

Moreover, this infrastructure funding has supported more urologists to put forward their ideas for clinical research. The TTU has worked closely with 17 chief investigators (CIs) from all across the UK to support the workup of 15 submitted grant applications, currently four being reviewed by funders, and four more in preparation for early 2024 submission. The scale of applications varies, the combined amount is over £15 million, but every application is multicentre, requiring clinical trials unit expertise for design and delivery if successful.

The clinical areas cover the four streams of urology health that The Urology Foundation supports research in (prostate, kidney, bladder, male reproductive organs). The research questions range from early phase research on medical device development through to natural experiments evaluating follow-up care after prostate cancer treatment. The TTU research managers have prepared applications and financial details for nine distinct funding platforms, greatly easing the administrative burden on CIs, letting them concentrate on the scientific aspect of applications. The TTU has made a significant impact in advancing urology research over the past three years and the charity is proud to have played an important part in its success.

### **TUF Grant Management System**

The charity currently has over 70 active grants and awards. In 2023 it was agreed that a Grants Management System be implemented to enable a more comprehensive / streamlined tracking of the status of the existing grants. The system will also enable reporting on awards across the four nations, regions, disease areas etc. The database could provide historical data for comparison, and also make it easier to collect information on research results and impact. A bespoke system has been developed - the TUF Grant Tracker facilitates the recording of applications, donors, recipients, reviewers, timelines, deliverable outputs, payments, and liabilities for each grant.

### **Patient and Public Involvement (PPI) Programme**

Individuals with experience of living with a disease or condition, or having significant others with a disease or condition, can bring substantial benefit and insight to charities. More and more charities are actively incorporating their experiences into conversations about the design of services, awareness programmes and medical research.



During the year the charity launched its Patient and Public Involvement (PPI) programme. The Programme will play a key role in acting as a bridge between the research community and people affected by urological cancers and conditions. The Programme is overseen by a PPI Development Board - members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgow), Hannah Warren (Trustee of The Urology Foundation), Helen Lake (Urology Nurse) and Susannah La-Touche (Urology Consultant at St George's University Hospital). A recruitment drive and series of events and webinars are scheduled for 2024.

## Our Research Strategy

Building on our achievements, we are developing our research strategy which will improve urological health and transform lives through research over the next five years. We are consulting with researchers, clinicians, nurses, allied healthcare professionals, decision makers and influencers, charity and industry partners, patients and their families as well as those with an interest in urology to help inform our strategy and identify key areas - from specific disease areas to health inequalities, prevention measures and treatments to training and improving care pathways. The strategy will launch in 2024.

### 3. Improving knowledge and skills through education and training

#### Fellowships

Fellowships enhance urological training, education, knowledge transfer and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. The Foundation offers a variety of different Fellowship opportunities.

#### *David Thompson Fellowship*

The David Thompson Fellowships are worth up to £35,000 per fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of specialty. Successful candidates will act as Ambassadors promoting best practice and sharing knowledge amongst their own team, hospital and wider urology community.

2023 was the inaugural year of the awards. The standard of applications was exceptionally high and a decision was made to award four Fellowships:

- Andrew Deytrikh, currently working in Sheffield, who will visit the University of British Columbia hospital in Vancouver, to learn more about robotic surgery for kidney & testicular cancer patients.
- Clare O'Connell, currently training in Dublin, who will visit University of Toronto to learn more about robotic surgery for kidney, bladder & testicular cancer patients.
- Eoin Dineen, currently at UCL, who will visit the Peter MacCallum Cancer Centre in Melbourne to undertake Prostate cancer surgery & research.
- Stefanie Croghan, currently in Dublin, who will undertake Newcastle Endourology Fellowship at the Freeman Hospital to learn more about Endourology and stone disease.

We are grateful to the Thompson Family Charitable Trust for enabling these Fellowships.



### **Malcolm Coptcoat Travelling Fellowship**

The Malcolm Coptcoat Fellowship, worth £5,000, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2023, its inaugural year, the Fellowship was awarded to Miss Eleanor Zimmerman, an ST6 Urology Specialist Registrar training at the Freeman Hospital, Newcastle. She will visit The Kulkarni Institute in Pune, India, a world-renowned centre for genito-urethral reconstruction, in particular urethroplasty. This high-volume unit performs in excess of 500 urethroplasties per year, with referrals received from not just across India, but also internationally. The unit regularly performs complex cases that are rarely seen or attempted in the UK, and the international training Professor Kulkarni and Dr Joshi offer is highly regarded and respected globally.

### **TUF/Urolink Fellowships**

The TUF/Urolink Fellowships, worth up to £1,500, are open to those senior level trainees who have completed their FRCS (Urol), enabling them to experience working in Low or Middle Income (LMIC) countries. The Fellowships help develop urological services in those countries as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than \$1,135 a year.

In 2023 four awards were made:

- Katie Brodie, a Urology ST6 at the Western General Hospital, Edinburgh
- Rory Ferguson, a Urology ST3 at Royal Cornwall Hospitals NHS Trust
- Wilson To, a Urology ST7 at Great Ormond Street Hospital for Children
- Danielle Whiting, a Urology ST6 at Royal Surrey County Hospital

All four will be visiting the Kilimanjaro Christian Medical Centre (KCMC) in Tanzania, to provide a mixture of teaching, training and hands-on surgery.

## **Support for urology trainees and urology nurses**

### **Keith Yeates Medal/Ralph Shackman prize**

The Medal and prize is conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2023 Dr Ben Odusaya, a trainee at Bolton NHS Foundation Trust, won the medal and the Shackman travelling fellowship worth £2,000. He will use the opportunity to attend a cadaveric masterclass in the use of HOLEP (Holmium laser enucleation of the prostate), a treatment for people with benign prostatic hyperplasia (BPH).

### **Nurse education and training**

We are committed to ensuring urology nurses and allied healthcare professionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician.

TUF's first Nurse Bursary, worth £2,000, was awarded to Catherine Borrington, a senior staff nurse at The Royal Oldham Hospital who is attending the PG Certificate in Urology at Edge Hill University. Catherine's aspiration is to become a Urology Clinical Nurse Specialist, supporting patients with benign and cancer diagnoses on treatment options and patient education, and helping to alleviate the consultant workload. We are grateful to the Charles Reynolds Foundation for funding these awards.



### **Regional Trainee Awards and Best of the Regions**

In 2023, the Foundation provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons (BAUS). There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall 'Best of the Regions' would be selected and win a further £500 prize. The overall winner in 2023 was George Sturgess, a trainee in the Yorkshire & Humber region, for his paper on Ketamine Uropathy: Clinical Experience in a High Prevalence Centre. George was invited to present his paper at the International Continence Society meeting taking place in Toronto.

### **Support for robotic surgery training**

Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy's Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures and videos with hands-on robotic surgery practice.

### **Supporting Advanced Consultant Training**

TUF funded the **Advanced Urology Simulation Boot Camp** course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role and provides training in often overlooked areas such as dealing with stress, effective leadership and the day-to-day challenges of consultant practice. The course was extremely well attended and received.

### **Support for travel and attending conferences and educational programmes**

During the year a number of small grants were made to urologists and nurses to travel to, or attend, training courses or conferences. Further small grants were also made for researchers to hold meetings with patients and stakeholders to understand further the impact of particular disease conditions.

## **Training and education**

As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions throughout the year on a range of topics. Highlights included:

- Working with Knowlex, who provide healthcare leaders and commissioning organisations with a range of resources, we took part in their 2023 Infection Prevention and Control Conference in Birmingham. This is Europe's largest Infection Prevention and Control Conference. TUF Trustee and Consultant Urologist Roland Morley presented on the subject of UTIs. We were also invited to run a webinar in March on the topic of "Female Urinary Incontinence Pathways: Where do they lead?" which brought together Mary Garthwaite (TUF's Chair), Mehwash Nadeem (Consultant Urological Surgeon at South Tees University Hospitals Trust) and Sarah Hillery (President of British Association of Urological Nurses).
- We were delighted to attend the British Association of Urological Surgeons (BAUS) Annual Conference in Birmingham and the British Association of Urological Nurses (BAUN) Annual Conference in Edinburgh. Both events provided the opportunity to meet with urology colleagues and industry.
- TUF's Chair was invited to speak at the Convatec Continence Care Customer Symposium in November which was attended by urology nurses, continence professionals, GPs and Convatec staff. TUF's Chair presented two sessions - 'The work of The Urology Foundation' and 'Patient choice in self-catheterisation care'.





## 4. Improving public awareness of urological cancers and conditions

The Urology Foundation is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

In April we hosted a Parliamentary Reception together with the Urology Trade Association (UTA) titled “Keeping patient choice at the heart of NHS and MedTec reform” at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy makers and industry attended the event.

In July we partnered with the MS Trust and the Spinal Injuries Association (SIA) to host a unique parliamentary event aimed at raising awareness of the challenges faced by people who use urinary catheters and encourage policy makers to talk about catheters and bladder issues. The event at the Churchill Room, House of Commons saw Parliamentarians participate in the Catheter Care Challenge, an escape-room style ‘challenge’, competing against colleagues to access a toilet, answering quick-fire questions about catheters and ultimately racing against the clock to complete the quiz and ‘catheterise’ safely. Paul Bristow MP hosted the event and we were joined by Parliamentarians including Sarah Owen MP (Lab), Margaret Ferrier MP (Independent), Christina Rees MP (Independent), Anna Firth MP (Con), Diana Mary Warwick and Baroness Warwick of Undercliffe (Lab). Sincere thanks to Coloplast for their support with the project.

### *“Help Us, Help You”*

A highlight of the year was the opportunity to take part in the NHSE Cancer Programme’s abdominal/urological “Help Us, Help You” symptoms awareness campaign and specifically the symptom “Blood in Pee”. These community-based events - held at indoor venues such as libraries, football stadiums and shopping centres - encouraged visitors worried by a “blood in pee” symptom to visit their GP or seek an early intervention. There was a particular focus on targeting black and minority ethnic groups, people from socio-economically deprived communities and people with other co-morbidities. In conjunction with the charity UCARE events were held across Oxfordshire and the London Boroughs of Newham and Tower Hamlets. London based events included Stratford Library, Better Gym, the Ideas Store and the East London Mosque.

### *Roundtable Events*

This year our CEO was invited to participate in a number of Roundtable discussions. Highlights included:

- In September she attended a cross-party Parliamentary Roundtable at the House of Commons “Harnessing innovation to address challenges in prostate cancer care” which brought together key stakeholders to discuss how the UK can better use innovations in diagnosis and treatment of prostate cancer to improve patient care. Guests included prostate cancer clinicians and patient group representatives.
- In October she attended the “Overcoming Inequalities in Cancer Care”, a Parliamentary drop-in event organised by Pfizer. The event provided an opportunity for Parliamentarians, clinicians and cancer charities to discuss the regional inequalities that exist in access to cancer care. Further discussions and activities are planned to look at ensuring patients and their families have better outcomes and experiences.

## Campaigns

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include:



- A campaign during Men's Health Week in partnership with Male Health platform TRTed to raise awareness of the underlying symptoms of Erectile Dysfunction and encourage men to talk about this issue. The campaign included a survey and the launch of a new Factsheet written by Mr Hussain M Alnajjar, Consultant Urological Surgeon and Andrologist, Honorary Associate Professor at University College London (UCL).
- As part of World Continence Week 2023 we worked with Convatec to develop a series of posters to highlight continence issues, to challenge the stigma and taboo that surrounds incontinence and to encourage people to seek help and support.

### ***Urology Awareness Month***

September is Urology Awareness Month, an annual campaign which brings together our urology community - researchers, urologists, nurses and allied health professionals, influencers and decision makers, patients and their families and those with an interest in urology health - to raise awareness of urological cancers and conditions. This year's theme was bladder health with a particular focus on urinary tract infections (UTIs), urinary incontinence and bladder cancer. Throughout the Month we highlighted stats and facts on bladder health alongside launching new videos, delivering webinars, Roadshows and health and well-being sessions. Highlights included:

- Knowlex invited TUF to run a webinar to mark the Month. TUF's Chair, Mary Garthwaite, together with Trustee and Consultant Urologist Roland Morley, President of BAUN Sarah Hillery and Locum Consultant Urological Surgeon Yasmin Abu Ghanem, presented a webinar 'Bladder Health: The Hidden Issue'. The webinar examined managing an overactive or under active bladder, the burden of urinary incontinence, bladder cancer and urinary tract infections (UTIs). Over 600 people registered for the event.
- Asda supermarket chain supported our London based Roadshows inviting customers and staff to learn about urology health.
- Together with Network Rail we were able to reach thousands of people through our health messages on their public notice boards at Manchester Piccadilly Station, Kings Cross Station and Liverpool Lime Street Station during September. We also had messaging on payroll slips that reached over 40,000 employees. TUF Chair, attended wellbeing sessions for Network Rail employees to highlight the signs and symptoms of urology conditions, including prostate cancer.
- TUF's Chair took part in a podcast on 'Why urology awareness matters'. This was part of Coloplast Professional's 'Stoma and Continence Conversations' podcast.

People were invited to support the campaign by holding events, posting messages of support on social media, displaying posters and given talks about urology health.

### **In the media**

1 in 2 of us will be affected by a urological cancer or condition yet these still don't attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and ensure better outcomes and a quality of life alongside raising awareness of The Urology Foundation and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highlights included an interview on Radio 4 Woman's Hour on the subject of UTIs and the proposed changes to prescribing - via the pharmacy setting - for uncomplicated UTIs. In June our Chair was interviewed on popular television show, Steph's Packed Lunch on the subject of male incontinence. As part of Men's Health Week, an erectile dysfunction campaign with the Men's Health platform, TRTed saw coverage in the Daily Mail, Huffington Post and Daily Star online.



## Appointment of the Director of Communications and Policy

In November the charity appointed its first Director of Communications and Policy, Laura Thorne. Laura has over ten years' experience in public affairs and communications, implementing national and local change, providing strategic advice and delivering targeted, awareness-raising campaigns. Prior to joining The Urology Foundation, she was Head of Health Public Affairs at a communications and marketing agency. Her expertise includes public affairs and policy; strategic campaigns; communications; issues management; and relationship building across Westminster and the devolved nations. She has worked collaboratively with pharmaceutical and MedTech companies, charities, patient groups, All-Party Parliamentary Groups and trade bodies to deliver positive change. She is a member of the Cancer52 Policy and Public Affairs Steering Group where she works to improve outcomes for people experiencing less common urology cancers. With over three years' experience working for a Member of Parliament, she also has a strong understanding of the workings of Parliament and Government.

## 5. Collaborations and partnerships

We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partners working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Research UK, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare.

We welcomed the opportunity to meet and work with a range of companies including Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Janssen, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health.

## 6. Investment in our Team

Developing our people and infrastructure is vital as it underpins the delivery of our charitable and fundraising activities. The Trustees have committed to infrastructure investment which will support sustainability, effectiveness, collaboration and impact particularly within the charity's programmes and grants portfolio which has expanded significantly over the last two years, across fundraising and the expansion of funding streams and to ensure we have a "voice" within the urology community - in driving change, improving outcomes and patient care.

The first stage of the investment saw the appointment of Laura Thorne as the new Director of Communications and Policy in November. Two new roles have been approved and recruitment will commence in January 2024:

- Fundraising Manager (Events and Individual Giving) to manage and expand a portfolio of events, to develop an individual giving programme and to grow the supporter base.
- Grants & Programmes Executive to support for the growing programmes and grants portfolio

## 7. Plans for the future

Our strategy "The Way Ahead 2023-2025" has set out a clear direction and our ambitions for the next three years. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders, in 2024 we will look to:

- Launch a new Research Strategy outlining how we will accelerate the progress and breakthroughs in urological research, the key disease area we will focus on and campaigning for further investment in research.
- Support our urology community and allied healthcare professionals through training and education, study and travel awards and other opportunities.



- Launch a UTI Programme to include a dedicated research grant call to better understand UTIs, a nurse-led UTI Information Service and training for health professionals.
- Develop a Communications Strategy to
  - Raise awareness of urology health and the work of The Urology Foundation
  - Drive change in urology care and practice through our policy work, campaigning and health awareness initiatives
  - Strengthen our partnerships


This will include the launch of a new website, information and promotional resources, media relations and our annual Urology Awareness Month campaign which will focus on Men's Urology Health.

- Give a voice to the people affected by or at risk of urological disease ensuring they have the opportunity to be heard, to influence and drive change. We will look to support and develop closer relationships with seldom heard communities, those at greater risk of specific disease and those with poorer outcomes.
- Build on our current work and achievements in prostate cancer, UTIs and bladder health.
- Invest in our fundraising programme with the launch a Fundraising Appeal to support the delivery of our new Research Strategy



## Financial Review

### Financial Results of Activities & Events



The total value of net assets held by The Urology Foundation on 31 December 2023 was £3,111,987 (2022 £2,640,341). The Foundation's fundraising activities and other initiatives during the course of 2023 generated a total of £1,384,437 of voluntary income (2022 £1,318,353) and a further £66,800 (2022 £30,980) from specific fundraising event income.

### Fundraising

The Foundation is reliant on voluntary income to fulfil its remit. Following a review of the charity's fundraising function in 2022, the decision was made to invest in this area in order to diversify the existing income streams and to look to increase the charity's income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income.

We are pleased to report income for year totalled £1,470,272 against the previous year total of £1,355,713. The following information summarises the various disciplines:

- Donations. Income from donations totalled £136,210. Our sincere thanks to everyone who has supported us during the year.
- Business Community. We are committed to working with a wide range of companies including those in the pharmaceutical and Med tech industry in order to meet our objectives. Under the direction of Lucy Noakes, our Business Development Manager we have significantly grown this area during the year alongside building and strengthening our existing relationships. With our partners we are raising awareness of urological cancers and conditions and driving change to ensure better outcomes for patients and their families. Highlights during the year include, partnering with Coloplast on the Catheter Care Challenge at the House of Commons which saw Parliamentarians participate in the Catheter Care Challenge. For World Continence Week we collaborated with Convatec and together challenged the taboos around continence - calling for people to foster more openness around the impact it can cause to quality of life. We hosted a Parliamentary Reception together with the Urology Trade Association (UTA) Parliamentary Reception "Keeping patient choice at the heart of NHS and MedTec reform" at the House of Commons. Over 90 patients, scientists and clinicians, charity partners, policy





makers and industry attended the event. Reaching different audiences is a key objective for us and last year we were delighted to partner with Network Rail Wellbeing champion to deliver urology focussed webinars for employees, with a special focus on men's health in urology. Looking ahead to 2024, we will further develop our relationship and look to explore new ones to help us grow and deliver more exciting projects. We are grateful for the generosity of our many corporate partners who continue to support our vital work.

- Trusts and Foundations. Income from a range of both small and large trusts and foundations totalled £1,248,227 and included support towards research, awareness, community-based projects, education and training. This included a grant from The UK Government Covid Medical Research Support Fund totalling £282,018 towards helping to sustain early-career researchers supported by medical research charities impacted by the COVID 29 pandemic.
- Events. We are pleased to report that supporters organised and took part in a wide range of events throughout the year. These included the TUF Trek to Namibia which saw our President Professor Roger Kirby and Trustee Roland Morley together with eight TUF supporters raise an incredible £65,000. The Great North Run saw five dedicated runners, led by Jo Creswell President of BAUS, take to the streets of Newcastle to raise £3,762. The ever popular London Landmarks Half Marathon (LLHM) saw five runners take to the streets of London to raise an incredible £4,664. Ride London cyclists raised over £2,000 and a Rock Choir Concert organised by supporter Anne Stotesbury raised £2,000. A highlight of 2023 was the Bike4TUF, London to Paris Cycle Ride, in June. This year marked the 10th anniversary of this popular and successful Bike4TUF Ride organised by consultants Ben Eddy, Ben Challacombe and TUF supporter David Plummer. An incredible £56,650 was raised for TUF. We are grateful to everyone who undertook various fundraising challenges for the charity

We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

## Reserves & Liquidity Policy

The Foundation currently has 'free reserves' of £2,213,621 (31 December 2022: £2,084,596). Our free reserves relate to un-designated unrestricted reserves. During the next financial year, the Trustees intend to transfer funds from unrestricted funds to designated funds.

The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at 12 months in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of €500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and Trustees' approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of €500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects.

The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.



## Statement of going concern

The Foundation's unrestricted net funds generated in 2023 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

## Investments Policy

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually.

The Board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 1.4% return over 2023.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc.

## Remuneration policy

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

## Pensions policy

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

## Equal opportunities and diversity policy

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (i.e. grant applicants) and suppliers.

## Principal risks and uncertainties

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept, updated and discussed by the Board of Trustees on a quarterly basis.



### ***Impact of war in Ukraine and economic outlook***

The ongoing war in Ukraine and wider economic outlook has broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

### ***Risks to Data***

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Adrian Joyce) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is reliant upon voluntary income as an annual source of funding. It is the role of the trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the cloud and this is secured using a two-step password verification. The charity's own day to day working documents are also stored on a cloud-based system. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by Trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other Trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord and by the fire service to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.



## Structure, Governance & Management

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

### Charity Governance Code

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the trustees, who meet three times each year including an Annual General Meeting.

### Trustee Recruitment, Training and Induction

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Trustees contribute to every aspect of the charity: governance; fundraising; financial planning; management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertise and networks whenever they are called upon.

### Appointment & Election

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years.

### *The Executive Team*

The Chief Executive, is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the board of trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

### *Scientific and Education Committee (SEC)*

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy.



The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

#### ***Research Review Panel***

The Research Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Scholarship Review Panel is made up of clinical trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website. They provide their services as volunteers and we are enormously grateful to them.

#### ***Finance Committee***

The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

#### ***IT Oversight Committee***

The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustees on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer.

### **Relationships with Related Parties**

The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees.

### **Representation on Other Bodies**

The charity is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The Urology Foundation is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

The charity is also a member of Cancer 52, Charities Research Involvement Group, the National Council for Voluntary Organisations (NCVO) and UNSEEN, a UK leading anti-slavery charity working with survivors, businesses, governments, police and NHS to end slavery.



## Reference and administrative details

The registered charity name is “The Urology Foundation” (sometimes referred to as “TUF”), a charity and a company limited by guarantee.

### Trustees

Ms Mary Garthwaite (*Chair*)  
Ms Angela Daniel (*Treasurer*)  
Mr Mark Becker (*Secretary*)  
Prof Grant Stewart (*Chair, SEC resigned 14 March 2023*)  
Prof Rakesh Heer (*Chair SEC, appt 14 March 2023*)  
Ms Hilary Baker (*appt 21 March 2024*)  
Mr Mo Belal (*appt 21 March 2024*)  
Mr Ben Challacombe  
Ms Jo Cresswell (*resigned 17 June 2024*)  
Mr Mike Griggs (*appt 1 January 2023*)  
Mr Adrian Joyce (*resigned 8 December 2023*)  
Prof Alan McNeill (*appt 10 Feb 2023*)  
Mr Roland Morley (*resigned 21 March 2024*)  
Mr Kieran O’Flynn (*appt 8 December 2023*)  
Mr Ian Pearce (*appt 17 July 2024*)  
Ms Julia Taylor (*appt 21 March 2024*)  
Ms Hannah Warren

### President

Prof Roger Kirby

### Patrons

Mr Handel Evans  
Sir Ranulph Fiennes OBE  
Mrs Rosemary Macaire  
Ms Jane Macquitty MBE  
Mr Steven Norris

### Ambassadors

Mr Alex Corbisiero  
Mr Stephen Fry  
Mrs Kate Holmes

### Chief Executive

Ms Rebecca Porta

### Registered Office

1-2 St Andrew’s Hill  
London  
EC4V 5BY

### Charity number

1128683 (England & Wales)

### Company number

06817868

### Auditors

Dunkley & Co Ltd  
Woodlands Grange, Woodlands Lane  
Bradley Stoke  
Bristol BS32 4JY

### Bankers

National Westminster Bank plc  
PO Box 2022  
10 Marylebone High Street  
London W1A 1FH

### Investment Manager

Rothschild Bank (CI) Limited  
St. Julian’s Court, St. Julian’s Avenue  
St. Peter Port  
Guernsey GY1 3UA





## Trustees' & Directors' Responsibilities in the Preparation of Financial Statements

The trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

### Auditor

Mr Matthew Dobbins (FCA), of Dunkley & Co Ltd. has agreed to act as Auditor.

### Statement as to disclosure of information to the auditor

The trustees and directors at the date of approval of this trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

  
Mary Garthwaite

Mary Garthwaite (Sep 26, 2024 17:27 GMT+1)

Mary Garthwaite, Chair

Date: 26/09/2024



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Opinion**

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the charitable company has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Responsibilities of trustees**

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

**Our responsibilities for the audit of the financial statements**

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Extent to which the audit was considered capable of detecting irregularities, including fraud

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion.

Identifying and assessing potential risks related to irregularities

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, we considered the following:

- The nature of the charitable sector, control environment and performance including the design of the organisation's remuneration policies;
- Any matters we identified, having obtained and reviewed the organisation's documentation of their policies and procedures relating to:
  - o Identifying, evaluating and complying with laws and regulations and whether they were aware of any instances of non-compliance;
  - o Detecting and responding to the risks of fraud and whether they have knowledge of any actual, suspected or alleged fraud;
  - o The internal controls established to mitigate risks of fraud or non-compliance with laws and regulations;
  - o The matters discussed among the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud.

As a result of these procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the areas of management override of controls, going concern, income recognition, and the appropriateness of expenditure.

We also obtained an understanding of the legal and regulatory framework that the organisation operates in, focusing on provisions of those laws and regulations that had a direct effect on the determination of material amounts and disclosures in the financial statements.

Audit response to risks identified

Our procedures to respond to risks identified included the following:

- Enquiring of management, concerning actual and potential litigation and claims;
- Substantive testing to vouch source records to the financial statements;
- Performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;



**Report of the Independent Auditors to the Trustees of  
The Urology Foundation (Registered number: 06817868)**

- Enquiring of management the internal controls in, evaluating each control for weakness and vouching to evidence of the control taking place;

- In addressing the risk of fraud through management override of controls, testing the appropriateness of journal entries and other adjustments; assessing whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

We also communicated relevant identified laws and regulations and potential fraud risks to all engagement team members, and remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable company's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

  
Matthew Dobbins (Sep 26, 2024 21:27 GMT+1)

Matthew Dobbins FCA  
Dunkley's  
Chartered Accountants  
Registered Auditors  
Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006  
Woodlands Grange  
Woodlands Lane  
Bradley Stoke  
Bristol  
BS32 4JY

Date: 26/09/2024  
Date: .....



THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2023

	Note	Unrestricted Funds £	Restricted Funds £	Total 2023 £	Total 2022 £
<b>INCOME</b>					
Donations and legacies	1	140,195	1,244,242	1,384,437	1,318,353
Other trading activities	2	66,800	-	66,800	30,980
Investments	3	19,035	-	19,035	6,380
<b>TOTAL INCOME</b>		<b>226,030</b>	<b>1,244,242</b>	<b>1,470,272</b>	<b>1,355,713</b>
<b>EXPENDITURE</b>					
<b>Raising Funds</b>					
Donations and legacies	4	24,761	11,091	35,852	43,308
Trading activities	5	21,357	15,959	37,315	42,830
Investment management costs		78	-	78	74
<b>Expenditure on Charitable activities</b>					
Raising Awareness	6	82,382	54,753	137,135	141,011
Grant making	7	198,193	879,886	1,078,079	680,136
Net losses/(Gains) on investment assets	11	(289,471)	(362)	(289,833)	255,897
<b>TOTAL EXPENDITURE</b>		<b>37,300</b>	<b>961,326</b>	<b>998,626</b>	<b>1,163,256</b>
<b>NET INCOME/(EXPENDITURE)</b>		<b>188,730</b>	<b>282,917</b>	<b>471,646</b>	<b>192,457</b>
<b>RECONCILIATION OF FUNDS</b>					
Fund balances brought forward at 1 January 2023		2,084,597	555,744	2,640,341	2,447,884
Transfer between funds		(59,706)	59,706	-	-
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2023</b>		<b>2,213,621</b>	<b>898,366</b>	<b>3,111,987</b>	<b>2,640,341</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 35 to 44 form part of these accounts*





THE UROLOGY FOUNDATION

STATEMENT OF FINANCIAL ACTIVITIES

for the year ended 31 December 2022 (Full fund comparative)

	Note	Unrestricted Funds £	Restricted Funds £	Total 2022 £
<b>INCOME</b>				
Donations and legacies	1	1,016,881	301,472	1,318,353
Other trading activities	2	30,980	-	30,980
Investments	3	6,380	-	6,380
<b>TOTAL INCOME</b>		<b>1,054,241</b>	<b>301,472</b>	<b>1,355,713</b>
<b>EXPENDITURE</b>				
<b>Raising Funds</b>				
Donations and legacies	4	38,978	4,330	43,308
Trading activities	5	38,547	4,283	42,830
Investment management costs		74	-	74
<b>Expenditure on Charitable activities</b>				
Raising Awareness	6	126,910	14,101	141,011
Grant making	7	606,675	73,461	680,136
Net (Gains) on investment assets	11	255,577	320	255,897
<b>NET INCOME/(EXPENDITURE)</b>		<b>1,066,761</b>	<b>96,495</b>	<b>1,163,256</b>
<b>NET (EXPENDITURE)</b>		<b>(12,520)</b>	<b>204,977</b>	<b>192,457</b>
<b>RECONCILIATION OF FUNDS</b>				
Fund balances brought forward at 1 January 2022		2,097,116	350,768	2,447,884
Transfer between funds		-	-	-
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2022</b>		<b>2,084,596</b>	<b>555,745</b>	<b>2,640,341</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 35 to 44 form part of these accounts*



# THE UROLOGY FOUNDATION

## BALANCE SHEET as at 31 December 2023

Company Number 06817868

	Note	2023 £	2022 £
<b>FIXED ASSETS</b>			
Tangible assets	10	3,895	2,719
Investments	11	3,453,644	3,407,104
		<u>3,457,540</u>	<u>3,409,823</u>
<b>CURRENT ASSETS</b>			
Debtors	12	440,181	413,449
Cash at bank and in hand		415,083	322,606
		<u>855,263</u>	<u>736,055</u>
<b>LIABILITIES: amounts falling due within one year</b>	13	966,337	1,102,738
<b>NET CURRENT LIABILITIES</b>		<u>(111,073)</u>	<u>(366,683)</u>
<b>LIABILITIES: amounts falling due in more than one year</b>	13	234,479	402,799
<b>NET ASSETS</b>		<u>3,111,987</u>	<u>2,640,341</u>
<b>THE FUNDS OF THE CHARITY</b>			
<b>Restricted income funds</b>	15		
Robotic Surgery Training Fund		106,448	160,170
Prostate Cancer Research Fund		208,149	137,269
Bladder Cancer Fund		344,862	184,851
Travel Fellowship Fund		0	648
Team Corbs - Testicular		7,313	7,311
Charles Reynolds		13,002	65,497
Thompson Family Charitable Trust		126,556	-
Innovation & Research Awards		85,197	-
Small Research Projects		0	-
Campaigns		0	-
Events		6,839	-
<b>Total Restricted income funds</b>		<u>898,366</u>	<u>555,744</u>
<b>Unrestricted income funds</b>	15		
General Fund		1,713,621	1,584,597
Designated Fund (British Urology Foundation)		500,000	500,000
<b>TOTAL CHARITY FUNDS</b>	16	<u>3,111,987</u>	<u>2,640,341</u>

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 25 to 28 were approved by the trustees and authorised for issue on 20 September 2024, and are signed on their behalf by

Mary Garthwaite  
Mary Garthwaite (Sep 26, 2024 17:27 GMT+1)  
..... Chair  
Mary Garthwaite

Angela Daniel  
Angela Daniel (Sep 26, 2024 21:58 GMT+2)  
..... Treasurer  
Angela Daniel

The notes on pages 35 to 44 form part of these accounts



THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS  
as at 31 December 2023

	Note	2023 £	2022 £
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>	14		
Net cash used in operating activities		(162,921)	84,134
<b>Cash flows from investing activities:</b>			
Dividends and interest from investments		14,039	5,855
Management fees paid from investments		(78)	(72)
Purchase of equipment		(1,856)	0
Transfer from cash		-	-
Proceeds from sale of investments		551,126	150
Purchase of investments		(307,833)	(5,882)
<b>Net cash used in investing activities:</b>		255,399	51
Change in cash and cash equivalents in the reporting period		92,477	84,185
Cash equivalents at the beginning of the reporting period		322,605	238,420
Cash and cash equivalents at the end of the reporting period		415,083	322,605

*The notes on pages 35 to 44 form part of these accounts*



## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2023

### ACCOUNTING POLICIES

---

#### BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102.

#### INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accruals basis. Deferred income represents revenues collected but not earned as of 31 December 2023. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

#### EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs, and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

#### TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance
------------------	----------------------

#### OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight line basis over the lease term.



## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2023

### ACCOUNTING POLICIES

---

#### INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

#### FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward in the balance sheet.

#### FOREIGN EXCHANGE

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

#### GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2024.

#### FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.



NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023

	Unrestricted funds £	Restricted funds £	2023 £	2022 £
<b>1. INCOME FROM DONATIONS AND LEGACIES</b>				
Grants received from charitable trusts and corporate sponsors	28,985	1,219,242	1,248,227	929,835
Donations	111,210	25,000	136,210	388,518
Legacies	-	-	-	-
	<u>140,195</u>	<u>1,244,242</u>	<u>1,384,437</u>	<u>1,318,353</u>
<b>2. INCOME FROM OTHER TRADING ACTIVITIES</b>				
Income from fundraising events	<u>66,800</u>	<u>-</u>	<u>66,800</u>	<u>30,980</u>
<b>3. INVESTMENT INCOME</b>				
Bank interest receivable on short term cash deposits	4,996	-	4,996	525
Income from investments listed on a recognised stock exchange:				
UK investments	14,039	-	14,039	5,855
Overseas investments	-	-	-	-
	<u>19,035</u>	<u>-</u>	<u>19,035</u>	<u>6,380</u>
<b>4. COSTS OF RAISING FUNDS VOLUNTARY INCOME</b>				
Direct costs	5,231	581	5,812	18,664
Support costs (see note 8)	19,530	10,509	30,040	24,644
	<u>24,761</u>	<u>11,091</u>	<u>35,852</u>	<u>43,308</u>





THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023

	Unrestricted funds £	Restricted funds £	2023 £	2022 £
<b>5. COSTS OF RAISING FUNDS TRADING ACTIVITIES</b>				
Costs of fundraising events	1,826	5,449	7,276	18,186
Support costs (see note 8)	19,530	10,509	30,040	24,644
	<u>21,357</u>	<u>15,959</u>	<u>37,315</u>	<u>42,830</u>
<b>6. COSTS OF RAISING AWARENESS</b>				
Costs of fundraising events	4,261	12,715	16,976	42,433
Support costs (see note 8)	78,121	42,038	120,159	98,578
	<u>82,382</u>	<u>54,753</u>	<u>137,135</u>	<u>141,011</u>
<b>7. GRANT MAKING</b>				
Innovation & Research Awards	-	435,592	435,592	-
iROC Bladder Cancer Trial	-	143,304	143,304	(2,342)
David Thompson Fellowship	-	120,000	120,000	-
Small Research Projects awarded to 6 (2022: 5) teams	-	55,759	55,759	38,914
Robotic Centres of Training	-	18,938	18,938	(1,050)
Research Scholarships awarded to 0 (2022: 5) individuals	-	(24,918)	(24,918)	369,082
Urolink Fellowship	1,493	-	1,493	4,500
BAUS	1,199	-	1,199	3,032
Burst	9,996	-	9,996	-
Keith Yeates medals awarded to 1 (2022: 5) individuals	1,415	-	1,415	10,000
Travel Grants	2,943	647	3,591	500
Other direct costs	26,001	-	26,001	-
BAUN/TUF Nurse	6,100	-	6,100	(2,083)
PPI in Research/patient engagement	-	-	-	39,203
Patient Advocacy Research	-	-	-	(4,449)
Awareness campaigns (WCW & UAM)	-	-	-	1,350
Movement in present value of grant accruals	5,824	-	5,824	42,752
	<u>54,971</u>	<u>749,321</u>	<u>804,292</u>	<u>499,409</u>
Salary costs		53,495	53,495	
Support costs (see note 8)	143,222	77,069	220,291	180,727
	<u>198,193</u>	<u>879,886</u>	<u>1,078,079</u>	<u>680,136</u>



NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2023 £	2022 £
<b>8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)</b>						
Staff costs (see note 9)	9,153	9,153	36,611	67,119	122,035	194,741
Other staff costs including recruitment	895	895	3,580	6,563	11,932	3,118
Committee and other staff welfare expenses	345	345	1,382	2,533	4,605	4,010
Other office costs	4,284	4,284	17,135	31,414	57,117	58,912
Audit fee	240	240	959	1,758	3,196	298
Accountancy and advisory services	1,030	1,030	4,121	7,556	13,738	10,518
Other costs	3,545	3,545	14,180	25,997	47,267	23,320
Depreciation-owned assets	38	38	154	282	513	816
	<u>19,530</u>	<u>19,530</u>	<u>78,121</u>	<u>143,222</u>	<u>260,403</u>	<u>295,733</u>
<b>8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)</b>						
Staff costs (see note 9)	2,989	2,989	11,955	21,918	39,851	21,638
Other staff costs including recruitment	292	292	1,169	2,143	3,896	347
Committee and other staff welfare expenses	113	113	451	827	1,504	445
Other office costs	5,531	5,531	22,123	40,558	73,742	6,546
Audit fee	78	78	313	574	1,044	32
Accountancy and advisory services	336	336	1,346	2,467	4,486	1,170
Other costs	1,158	1,158	4,631	8,489	15,435	2,590
Depreciation-owned assets	13	13	50	92	167	91
	<u>10,509</u>	<u>10,509</u>	<u>42,038</u>	<u>77,069</u>	<u>140,126</u>	<u>32,859</u>



## THE UROLOGY FOUNDATION

### NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2023

		2023	2022
		No.	No.
9.	<b>STAFF COSTS</b>		
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:			
Office and administration		3.7	3.3
		£	£
Staff costs for the above persons:			
Staff	Wages and salaries	105,352	137,779
Staff	Social security costs	8,376	13,374
Key management personnel	Wages and salaries	92,700	59,655
Key management personnel	Social security costs	8,954	5,571
		215,382	216,379

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2023 (2022: 2). The total emoluments of these employees during the year were in the following ranges:

		2023	2022
£100,000 - £110,000	No.	1	0
£90,000 - £100,000	No.	0	1
£60,000 - £70,000	No.	0	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increase either incremental or cost of living.

No Director received any remuneration from the Company during the year (2022: £nil).

No trustee received any remuneration for services provided to the charity during the current or previous period. Trustees expenses reimbursed in respect of Trustee's meetings and travel for the year ended 31st December 2023 amounted to £0 paid to no Trustees (2022 £0 paid to no Trustees).

10.	<b>TANGIBLE ASSETS</b>	<b>Office Equipment</b>
		£
Cost:		
1 January 2023		22,494
Additions		1,856
31 December 2023		24,350
Depreciation:		
1 January 2023		19,775
Charge for year		680
31 December 2023		20,455
Net book value:		
31 December 2023		3,895
31 December 2022		2,719



THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023

		2023 £	2022 £
<b>11.</b>	<b>INVESTMENTS</b>		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2023	3,407,104	3,657,270
	Transfers from cash		
	Additions at cost	307,833	5,882
	Disposal proceeds	(551,126)	(150)
	Realised gains	3	29
	Unrealised (losses)/gains	289,830	(255,926)
	31 December 2023	<u>3,453,644</u>	<u>3,407,104</u>
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,453,644	3,407,104
		<u>3,453,644</u>	<u>3,407,104</u>
	Fixed income securities	306,382	549,597
	Multi-Asset & Hybrid Instruments	3,147,262	2,857,508
		<u>3,453,644</u>	<u>3,407,104</u>
	At the balance sheet date, the historical cost of the investments was £2,700,892 (2022: £2,944,132). The following holdings had a value of >5% of the market value of the investments:		
		<b>Value £ 2023</b>	<b>Value £ 2022</b>
	<b>Name</b>		
	<b>Holding</b>		
	Rothschild & Co WM SICAV-SIF Exbury Fund GBP	3,147,262	2,857,508
	Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs		-
	InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fund	306,382	549,597
<b>12.</b>	<b>DEBTORS</b>	<b>2023 £</b>	<b>2022 £</b>
	Amounts falling due within one year:		
	Prepayments	18,978	14,086
	Accrued Income	421,203	399,363
		<u>440,181</u>	<u>413,449</u>



NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2023

13.	CREDITORS	2023 £	2022 £			
Amounts falling due within one year:						
Deferred income	13,382	504				
Trade creditors	150,500	-				
General accruals	7,183	45,971				
Grant accruals	795,272	1,049,953				
Other creditors	-	6,310				
	<u>966,337</u>	<u>1,102,738</u>				
Deferred income b/fwd at 1 January 2023	504					
Amounts released in the year	(504)					
New amounts deferred in the year	13,382					
Deferred income c/fwd at 31 December 2023	<u>13,382</u>					
CREDITORS	2023 £	2022 £				
Amounts falling due in more than one year:						
Grant accruals	234,479	402,799				
	<u>234,479</u>	<u>402,799</u>				
14.	RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES					
Net Income/(expenditure) for the reporting period per the statement of financial activities						
	471,646	192,458				
Adjustments for:						
Depreciation charges	680	907				
Losses/(gains) on investments	(289,833)	255,897				
Dividends and interest from investments	(14,039)	(5,855)				
Management fees paid from investments	78	72				
(Increase) in debtors	(26,732)	(314,726)				
(Decrease) in creditors	(304,721)	(44,619)				
Net cash used in operating activities	<u>(162,921)</u>	<u>84,134</u>				
15.	THE FUNDS OF THE CHARITY					
	1 January 2023 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2023 £
Restricted income funds:						
Robotic Surgery						
Training Fund	160,170	-	-	(53,765)	43	106,448
Prostate Cancer Research Fund	137,269	-	45,879	24,918	84	208,149
Bladder Cancer Fund	184,851	-	359,000	(199,128)	139	344,862
Travel Fellowship Fund	648	-	-	(648)	0	0
Team Corbs - Testicular	7,311	-	-	-	3	7,313
Charles Reynolds	65,497	(52,500)	-	-	5	13,002
Thompson Family Charitable Trust	-	-	300,000	(173,495)	51	126,556
Innovation & Research Awards	-	72,500	491,614	(478,951)	34	85,197
Small Research Projects	-	51,456	11,000	(62,456)	0	0
Campaigns	-	(11,750)	11,750	-	0	0
Events	-	-	25,000	(18,164)	3	6,839
	<u>555,744</u>	<u>59,706</u>	<u>1,244,242</u>	<u>(961,689)</u>	<u>362</u>	<u>898,366</u>
Unrestricted income funds:						
General Fund	1,584,597	(59,706)	226,030	(326,771)	289,471	1,713,621
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	<u>2,640,341</u>	<u>-</u>	<u>1,470,272</u>	<u>(1,288,460)</u>	<u>289,833</u>	<u>3,111,987</u>



**15. THE FUNDS OF THE CHARITY (Continued)**

- The Trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the Trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long term basis.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder Cancer Fund: Thanks to the generosity of the Champniss Foundation and the Champniss Charitable Trust, The Urology Foundation has been able to support a number of projects, including research projects tracking patients' fitness post cancer surgery and to predict complications arising during and post
- Prostate Cancer Research - Thanks to the support of the John Black Charitable Foundation, The Urology Foundation has been able to support a number of projects furthering our understanding of prostate cancer and its treatments. Two further research grants were awarded in 2023.
- Team Corbs: The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.
- Charles Reynolds funds are put towards supporting a number of our research projects and to support education and training for urology nurses, in particular through nurse bursaries and travel grants.
- The Thompson Family Charitable Trust generously support our charitable aims and objectives, in particular support of research and training, and through funding the David Thompson Fellowships. 2023 was in the inaugural year of the Fellowships and four awards were made.
- Innovation & Research Awards. These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions.
- Small Research projects. These awards are primarily about studies that might improve patient pathways or treatment and care. Projects are worth £10,000 each.
- Campaigns - As part of the NHSE Cancer Programme's abdominal/urological "Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee", a series of community based events were delivered across London. Visitors worried about a "blood in pee" symptom were encouraged to visit their GP or seek an early intervention.
- Events - The Foundation was pleased to receive support towards the TUF Trek to Namibia.





## 16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Net Assets/(Liabilities) £	Total £
<b>Restricted income funds:</b>			
Robotic Surgery Training Fund	118,135	(11,687)	106,448
Prostate Cancer Research Fund	231,002	(22,853)	208,149
Bladder Cancer Fund	382,723	(37,862)	344,862
Travel Fellowship Fund	0	0	0
Team Corbs - Testicular	8,117	(804)	7,313
Charles Reynolds	14,429	(1,428)	13,002
Thompson Family Charitable Trust	140,450	(13,894)	126,556
Innovation & Research Awards	94,550	(9,354)	85,197
Small Research Projects	0	0	0
Campaigns	0	0	0
Events	7,590	(751)	6,839
<b>Unrestricted income funds:</b>			
General Fund	1,901,754	(188,133)	1,713,621
Designated Fund (British Urology Foundation)	554,893	(54,893)	500,000
<b>NET ASSETS</b>	<b>3,453,644</b>	<b>(341,658)</b>	<b>3,111,987</b>

## 17. ULTIMATE CONTROLLING PARTY

The Charity is controlled by the board of Trustees.

## 18. COMMITMENTS UNDER OPERATING LEASES

As at 31st December 2023, the Charity had annualised operating commitments under non-cancellable operating leases expiring as follows:

	2023 £	2022 £
Expiring within one year		
- Land and Buildings	12,500	10,937
- Others	-	-
	<u>12,500</u>	<u>10,937</u>
Expiring within two to five years		
- Land and Buildings	-	12,500
- Others	-	-
	<u>-</u>	<u>12,500</u>

## 19. CONTINGENT ASSETS

There were no contingent assets as at 31 December 2023.

## 20. RELATED PARTY TRANSACTIONS

During the year, travel expenses amounting to £2,257 were reimbursed to the Trustees. Donations of £240 were received from the Trustees. No further transactions were undertaken such as are required to be disclosed under FRS 102 or the Charities Act.

